Sk Biopharmaceutica Valuation
| 326030 Stock | 102,100 1,500 1.45% |
At this time, the company appears to be overvalued. Sk Biopharmaceuticals owns a latest Real Value of USD89355.0 per share. The recent price of the company is USD102100.0. Our model measures the value of Sk Biopharmaceuticals from evaluating the company fundamentals such as Current Valuation of 5.87 T, return on equity of -0.12, and Profit Margin of (0.12) % as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sk Biopharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Sk Biopharmaceuticals is based on 3 months time horizon. Increasing Sk Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sk Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 326030 Stock. However, Sk Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 102100.0 | Real 89355.0 | Hype 102100.0 | Naive 96387.58 |
The real value of 326030 Stock, also known as its intrinsic value, is the underlying worth of Sk Biopharmaceuticals Company, which is reflected in its stock price. It is based on Sk Biopharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Sk Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Sk Biopharmaceuticals Co helps investors to forecast how 326030 stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sk Biopharmaceutica more accurately as focusing exclusively on Sk Biopharmaceutica's fundamentals will not take into account other important factors: Sk Biopharmaceutica Total Value Analysis
Sk Biopharmaceuticals Co is presently forecasted to have takeover price of 5.87 T with market capitalization of 5.32 T, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sk Biopharmaceutica fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.87 T | 5.32 T |
Sk Biopharmaceutica Investor Information
About 64.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 117.74. Sk Biopharmaceuticals had not issued any dividends in recent years. Based on the key measurements obtained from Sk Biopharmaceutica's financial statements, Sk Biopharmaceuticals Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Sk Biopharmaceutica Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sk Biopharmaceutica has an asset utilization ratio of 65.04 percent. This suggests that the Company is making USD0.65 for each dollar of assets. An increasing asset utilization means that Sk Biopharmaceuticals Co is more efficient with each dollar of assets it utilizes for everyday operations.Sk Biopharmaceutica Ownership Allocation
Sk Biopharmaceuticals secures a total of 78.31 Million outstanding shares. Sk Biopharmaceuticals owns majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.28 % of Sk Biopharmaceuticals Co outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.Sk Biopharmaceutica Profitability Analysis
The company reported the revenue of 418.64 B. Net Income was 64.85 B with profit before overhead, payroll, taxes, and interest of 396.31 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Sk Biopharmaceutica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Sk Biopharmaceutica and how it compares across the competition.
About Sk Biopharmaceutica Valuation
The stock valuation mechanism determines Sk Biopharmaceutica's current worth on a weekly basis. Our valuation model uses a comparative analysis of Sk Biopharmaceutica. We calculate exposure to Sk Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sk Biopharmaceutica's related companies.8 Steps to conduct Sk Biopharmaceutica's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sk Biopharmaceutica's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sk Biopharmaceutica's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sk Biopharmaceutica's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sk Biopharmaceutica's revenue streams: Identify Sk Biopharmaceutica's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sk Biopharmaceutica's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sk Biopharmaceutica's growth potential: Evaluate Sk Biopharmaceutica's management, business model, and growth potential.
- Determine Sk Biopharmaceutica's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sk Biopharmaceutica's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for 326030 Stock analysis
When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |